GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (STU:1AEA) » Definitions » Future 3-5Y Total Revenue Growth Rate

argenx SE (STU:1AEA) Future 3-5Y Total Revenue Growth Rate : 34.42 (As of May. 24, 2025)


View and export this data going back to 2019. Start your Free Trial

What is argenx SE Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, argenx SE's Future 3-5Y Total Revenue Growth Rate is 34.42.


Competitive Comparison of argenx SE's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, argenx SE's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where argenx SE's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

argenx SE  (STU:1AEA) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


argenx SE Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of argenx SE's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (STU:1AEA) » Definitions » Future 3-5Y Total Revenue Growth Rate
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines